NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Gary,

Happy holidays!

I think my post was not clear enough. All new trials after Jan. 31, 2023 have to be registered. I don't think an inquiry call to the school would be helpful as I am sure this trial is highly confidential.

https://www.clinicaltrialsregister.eu/

My conjecture is that the trial is DCVax-L + Poly-ICLC + Keytruda since I strongly believe after 2016 DCVax-L by default always means DCVax-L + Poly-ICLC.

If the combination of the three can trigger antitumor response so intense that rGBM patients had to go through surgery to remove the inflammation tissue, I have no doubt the results on colorectal cancer would be amazing too. I assume in colorectal cancer case the patients don't need surgery to deal with inflammation tissue since there is always room to accommodate the expansion outside skull.

I have medical background. The above is my speculation.